Please login to the form below

Not currently logged in
Email:
Password:

tivantinib

This page shows the latest tivantinib news and features for those working in and with pharma, biotech and healthcare.

Daiichi Sankyo to shut down German antibody unit U3

Daiichi Sankyo to shut down German antibody unit U3

Daiichi Sankyo is looking to new products such as novel oral anticoagulant (NOAC) Lixiana (edoxaban) - as well as pipeline candidates like tivantinib for liver cancer, quizartinib for leukaemia and mirogabalin for

Latest news

  • Daiichi Sankyo cuts a swathe through US workforce Daiichi Sankyo cuts a swathe through US workforce

    These include tivantinib for liver cancer - tipped by some analysts as a $600m product despite disappointing data in lung cancer - quizartinib for leukaemia and mirogabalin for fibromyalgia.

  • Roche drug fails in lung cancer trial Roche drug fails in lung cancer trial

    It remains to be seen whether the failed study has implications for other c-MET inhibitors in clinical trials, although the class has had other notable casualties, including ArQule's tivantinib

  • Daiichi, ArQule cancer drug tivantinib flunks another trial Daiichi, ArQule cancer drug tivantinib flunks another trial

    Tivantinib is a first in-class inhibitor of MET, a receptor tyrosine kinase thought to play a role in the development of a number of human cancers. ... to proceed with further clinical development of tivantinib in this tumour type ". 14th January 2013.

  • Russian market for lung cancer drugs to hit $163m by 2015

    Kirin's tivantinib - should make their debut in or before 2015.". ... Meanwhile, Daiichi Sankyo began enrolling patients in Europe into a large, multinational phase III trial of tivantinib, its investigational small molecule inhibitor of the c-MET

  • Non-small cell lung cancer research

    A combination of tivantinib and erlotinib is being compared with erlotinib alone in two phase III trials. ... The primary endpoint of both studies is overall survival. InThought rates tivantinib as having a 58 per cent probability of approval.

More from news
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...

Infographics